A peculiar case of psychosis: anti-NMDAr encephalitis

Kouba, Lamia; Alhosain, Dalia

doi:10.1186/s12245-021-00389-y

Cited by 2 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vidarabine, an antiviral mainly used against herpes simplex virus, has been reported to improve a patient's schizo-affective disorder possibly induced by the viral infection as per a case study reported by Schlitt et al [91]. Associations of herpes simplex virus to schizophrenia have been found not only in the immediate viral carriers but also in their offspring [92][93][94].…”

Section: Discussionmentioning

confidence: 99%

Network-based drug repurposing for schizophrenia

Truong,

Liu,

Panizzutti

et al. 2024

Neuropsychopharmacol.

View full text Add to dashboard Cite

Despite recent progress, the challenges in drug discovery for schizophrenia persist. However, computational drug repurposing has gained popularity as it leverages the wealth of expanding biomedical databases. Network analyses provide a comprehensive understanding of transcription factor (TF) regulatory effects through gene regulatory networks, which capture the interactions between TFs and target genes by integrating various lines of evidence. Using the PANDA algorithm, we examined the topological variances in TF-gene regulatory networks between individuals with schizophrenia and healthy controls. This algorithm incorporates binding motifs, protein interactions, and gene co-expression data. To identify these differences, we subtracted the edge weights of the healthy control network from those of the schizophrenia network. The resulting differential network was then analysed using the CLUEreg tool in the GRAND database. This tool employs differential network signatures to identify drugs that potentially target the gene signature associated with the disease. Our analysis utilised a large RNA-seq dataset comprising 532 post-mortem brain samples from the CommonMind project. We constructed co-expression gene regulatory networks for both schizophrenia cases and healthy control subjects, incorporating 15,831 genes and 413 overlapping TFs. Through drug repurposing, we identified 18 promising candidates for repurposing as potential treatments for schizophrenia. The analysis of TF-gene regulatory networks revealed that the TFs in schizophrenia predominantly regulate pathways associated with energy metabolism, immune response, cell adhesion, and thyroid hormone signalling. These pathways represent significant targets for therapeutic intervention. The identified drug repurposing candidates likely act through TF-targeted pathways. These promising candidates, particularly those with preclinical evidence such as rimonabant and kaempferol, warrant further investigation into their potential mechanisms of action and efficacy in alleviating the symptoms of schizophrenia.

show abstract

Section: Discussionmentioning

confidence: 99%